Patients immediately welcomed the confirmation of health insurance benefits of the acute lymphocytic leukemia and lymphoma CAR-T treatment Kymriah (Tisagencleucel).

The patients urged the transition committee of the next presidential post and Yoon Seok-yeol to quickly register new drugs directly related to life as health insurance benefits.

On the 31st, Korea Leukemia patient organization said, "The cost of one-time non-reimbursement payment is 460 million won, and the ultra-high-priced Kymriah passed the Health Policy Review Committee and acquired health insurance benefits to even hope for cure." Kymriah will be listed with an upper limit of 360 million won for one-time health insurance